Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)
| العنوان: | Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta) |
|---|---|
| المؤلفون: | Kathrin Eschke, Theresa C. Firsching, Volker Thiel, Nikolaus Osterrieder, Tran Thi Nhu Thao, Jakob Trimpert, Dusan Kunec, Julia Adler, Azza Abdelgawad, Nadine Ebert, Achim D. Gruber |
| المصدر: | Science advances Science Advances Trimpert, Jakob; Adler, Julia M; Eschke, Kathrin; Abdelgawad, Azza; Firsching, Theresa C; Ebert, Nadine; Tran, Thi Nhu Thao; Gruber, Achim D; Thiel, Volker; Osterrieder, Nikolaus; Kunec, Dusan (2021). Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). Science Advances, 7(49), eabk0172. American Association for the Advancement of Science 10.1126/sciadv.abk0172 <http://dx.doi.org/10.1126/sciadv.abk0172> |
| بيانات النشر: | American Association for the Advancement of Science, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Multidisciplinary, Attenuated vaccine, 630 Agriculture, Epidemiology, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SciAdv r-articles, Alpha (ethology), 610 Medicine & health, 500 Science, Virology, Coronavirus, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Medicine, 570 Life sciences, biology, 590 Animals (Zoology), Biomedicine and Life Sciences, Health and Medicine, Beta (finance), business, ComputingMilieux_MISCELLANEOUS, Research Article |
| الوصف: | Description A single intranasal vaccination with live attenuated virus provides protection against VOC B.1.1.7 (Alpha) and B.1.351 (Beta). Vaccines are instrumental and indispensable in the fight against the COVID-19 pandemic. Several recent SARS-CoV-2 variants are more transmissible and evade infection- or vaccine-induced protection. We constructed live attenuated vaccine candidates by large-scale recoding of the SARS-CoV-2 genome and showed that the lead candidate, designated sCPD9, protects Syrian hamsters from a challenge with ancestral virus. Here, we assessed immunogenicity and protective efficacy of sCPD9 in the Roborovski dwarf hamster, a nontransgenic rodent species that is highly susceptible to SARS-CoV-2 and severe COVID-19–like disease. We show that a single intranasal vaccination with sCPD9 elicited strong cross-neutralizing antibody responses against four current SARS-CoV-2 variants of concern, B.1.1.7 (Alpha), B.1.351 (Beta), B.1.1.28.1 (Gamma), and B.1.617.2 (Delta). The sCPD9 vaccine offered complete protection from COVID-19–like disease caused by the ancestral SARS-CoV-2 variant B.1 and the two variants of concern B.1.1.7 and B.1.351. |
| وصف الملف: | application/pdf |
| DOI: | 10.48350/165648 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48e99fddc063211a177368c7b5196571 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....48e99fddc063211a177368c7b5196571 |
| قاعدة البيانات: | OpenAIRE |
| DOI: | 10.48350/165648 |
|---|